Oncogenes in myeloproliferative disorders
A Tefferi, DG Gilliland - Cell cycle, 2007 - Taylor & Francis
Myeloproliferative disorders (MPDs) constitute a group of hematopoietic malignancies that
feature enhanced proliferation and survival of one or more myeloid lineage cells. William …
feature enhanced proliferation and survival of one or more myeloid lineage cells. William …
Molecular drug targets in myeloproliferative neoplasms: mutant ABL1, JAK2, MPL, KIT, PDGFRA, PDGFRB and FGFR1
A Tefferi - Journal of cellular and molecular medicine, 2009 - Wiley Online Library
• Introduction‐BCR‐ABL1‐ABL1‐BCR‐ABL1‐Anti‐BCR‐ABL1 targeted therapy in CML‐
Imatinib resistance and second‐generation anti‐BCR‐ABL1 kinase inhibitors‐Other ABL1 …
Imatinib resistance and second‐generation anti‐BCR‐ABL1 kinase inhibitors‐Other ABL1 …
Fusions involving protein kinase C and membrane-associated proteins in benign fibrous histiocytoma
A Płaszczyca, J Nilsson, L Magnusson, O Brosjö… - … International Journal of …, 2014 - Elsevier
Benign fibrous histiocytoma (BFH) is a mesenchymal tumor that most often occurs in the skin
(so-called dermatofibroma), but may also appear in soft tissues (so-called deep BFH) and in …
(so-called dermatofibroma), but may also appear in soft tissues (so-called deep BFH) and in …
Mechanisms of STAT protein activation by oncogenic KIT mutants in neoplastic mast cells
Mutations in the c-kit gene occur in the vast majority of mastocytosis. In adult patients as well
as in the cell line derived from mast cell neoplasms, the mutations occur almost exclusively …
as in the cell line derived from mast cell neoplasms, the mutations occur almost exclusively …
Recent advances in the molecular biology of systemic mastocytosis: implications for diagnosis, prognosis, and therapy
M Martelli, C Monaldi, S De Santis, S Bruno… - International Journal of …, 2020 - mdpi.com
In recent years, molecular characterization and management of patients with systemic
mastocytosis (SM) have greatly benefited from the application of advanced technologies …
mastocytosis (SM) have greatly benefited from the application of advanced technologies …
The tyrosine kinase FES is an essential effector of KITD816V proliferation signal
E Voisset, S Lopez, P Dubreuil… - Blood, The Journal of …, 2007 - ashpublications.org
KIT is a tyrosine kinase receptor that is aberrantly activated in several neoplasms. In human
pathologies, the most frequent mutation of KIT occurs at codon 816. The resulting KIT mutant …
pathologies, the most frequent mutation of KIT occurs at codon 816. The resulting KIT mutant …
Classification of chronic myeloid disorders: from Dameshek towards a semi-molecular system
A Tefferi, G Gilliland - Best Practice & Research Clinical Haematology, 2006 - Elsevier
Hematological malignancies are phenotypically organized into lymphoid and myeloid
disorders, although such a distinction might not be precise from the standpoint of lineage …
disorders, although such a distinction might not be precise from the standpoint of lineage …
Effects of stem cell factor on hypoxia-inducible factor 1 alpha accumulation in human acute myeloid leukaemia and LAD2 mast cells
BF Gibbs, IM Yasinska, AE Oniku, VV Sumbayev - PloS one, 2011 - journals.plos.org
Stem cell factor (SCF) is a hematopoietic growth factor that exerts its activity by signalling
through the tyrosine kinase receptor known as Kit or CD117. SCF-Kit signalling is crucial for …
through the tyrosine kinase receptor known as Kit or CD117. SCF-Kit signalling is crucial for …
The c-Kit/D816V mutation eliminates the differences in signal transduction and biological responses between two isoforms of c-Kit
M Pedersen, L Rönnstrand, J Sun - Cellular signalling, 2009 - Elsevier
Activating mutations of codon 816 of the Kit gene have been implicated in malignant cell
growth of acute myeloid leukemia (AML), systemic mastocytosis and germ cell tumors …
growth of acute myeloid leukemia (AML), systemic mastocytosis and germ cell tumors …